September 24, 2025 |
Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across Inizio Evoke, Inizio Engage, and Inizio Medical.

We’re proud to announce that our teams across Inizio Evoke, Inizio Engage, and Inizio Medical have been named finalists in six prestigious categories at the 2025 PM360 Trailblazer Awards, which recognize excellence and innovation in healthcare marketing.
The PM360 Trailblazer Awards honor the most impactful initiatives, strategies, and companies driving change in the healthcare industry across eight core categories. This year, our recognition spans multiple disciplines – highlighting our expertise in artificial intelligence (AI), data analytics, patient and healthcare professional (HCP) education, and persistence/adherence programs, as well as our standing as a top industry partner.
These finalist recognitions demonstrate how our connected capabilities empower life sciences organizations to achieve greater patient engagement, educational impact, and data-driven decision-making. Our work leverages cutting-edge AI and analytics, compelling creative strategies, and deep scientific expertise to deliver measurable results for our clients and ultimately improve healthcare outcomes.
We are honored to be recognized alongside such inspiring organizations and partners. These six finalist nominations reflect the passion, creativity, and expertise of our teams across Inizio.
Good luck to all of this year’s finalists – we look forward to celebrating the incredible work shaping the future of healthcare marketing. Stay tuned for the results and follow our updates on LinkedIn.
This content was provided by Inizio
Latest Content from Inizio
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence
Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the…
